LAS VEGAS, NV--(Marketwired - Aug 14, 2014) - Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI) through its wholly owned subsidiary Kintari, is pleased to announce the addition of Rob Barnes as Director of Sales. Rob will lead Kintari's sales globally.
Rob brings over two decades of direct sales experience to Kintari's already strong team of experienced sales, marketing and product development personnel. He will be responsible for developing the initial sales team and meeting aggressive sales objectives utilizing an independent sales force. The direct sales industry is nothing new to Rob as he was the founder and CEO of Sensaria Natural Bodycare, which he launched in 1999. He grew his company from a small business with initial annual sales of $100K to become a recognized company in the direct sales skincare market with over 5,000 independent distributors and annual revenues in excess of $20 million. In addition, Rob served on the Board of the US Direct Selling Association for three years.
"My excitement and expectations for Kintari could not be greater," said Rob. "Since leaving Sensaria I have longed for the opportunity to be involved in the direct sales industry again, but in my heart I knew it would take something special. Kintari products utilizing Skinvisible's patented Invisicare technology is that something special. It is unique, distinctive and proven by science and research. This technology will ignite the independent sales force and provide a unique opportunity that I believe is only available to Kintari. We will truly be "one of a kind" in the direct sales market place."
Skinvisible has added additional staff to facilitate the development and production of products supplied to Kintari. Skinvisible announces the addition of Joy Sanchez to oversee raw material and product production. Joy brings with her a unique combination of international supply chain, production and direct sales experience gained from over twenty years at various divisions of Avon Products, Inc. Joy has a Bachelor degree in Microbiology and is working on her Master's degree.
"We are pleased to add such high caliber staff to our company," said Mr. Terry Howlett, CEO of Skinvisible. "Rob is a seasoned professional with invaluable direct sales experience as well as having a proven track record for success and a wealth of enthusiasm for Kintari products. He has an energetic, true entrepreneurial drive and will be a key asset to the success of Kintari." He added, "Joy brings with her an impressive background in the industry and understands what is required to get production done on time and within budget. These additions could not have come at a more appropriate time as our Kintari Q4 launch planning is underway."
In line with Kintari's direct sales strategy, Skinvisible Pharmaceuticals, Inc. will continue to build its patent portfolio and to continue its core business of licensing over-the-counter and prescription product line focused on dermatology conditions.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible's wholly-owned subsidiary Kintari will commercialize cosmeceutical and OTC products globally through a direct sales channel.www.skinvisible.com www.invisicare.com .
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2014).